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Probing Structural Selectivity of Synthetic Heparin Binding
to Stabilin Protein Receptors
Elizabeth H. Pempe,1 Yongmei Xu,1 Sandhya Gopalakrishnan,2 Jian Liu,1 and Edward N. Harris2
1. Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill,
North Carolina 27599
2. Department of Biochemistry, University of Nebraska–Lincoln, Lincoln, Nebraska 68588
Corresponding author — E. Harris, Department of Biochemistry, University of Nebraska–Lincoln, 1901 Vine St., Lincoln, NE 68588; tel
402 472-7468, email eharris5@unl.edu

Background: Stabilin-2 is expressed in the liver endothelium and serves as the primary heparin clearance receptor in mammals.
Results: Increased sulfation and length of heparin increase affinity for Stabilin binding/endocytosis.
Conclusion: The data demonstrate that 3-O-sulfation is not required, but greatly enhances binding to the Stabilin receptors.
Significance: Customized heparin may have therapeutic applications for obtaining the optimal balance between anticoagulation and
clearance.
Abstract
As one of the most widely used drugs worldwide, heparin is an
essential anticoagulant required for surgery, dialysis, treatment
of thrombosis, cancer, and general circulatory management. Stabilin-2 is a scavenger clearance receptor with high expression
in the sinusoidal endothelium of liver. It is believed that Stabilin-2 is the primary receptor for the clearance of unfractionated
and low molecular weight heparins in the liver. Here, we identify the modifications and length of the heparin polymer that are
required for binding and endocytosis by both human Stabilin receptors: Stabilin-2 and its homolog Stabilin-1 (also found in liver
endothelium). Using enzymatically synthesized 35S-labeled heparan sulfate oligomers, we identified that sulfation of the 3-OH
position of N-sulfated glucosamine (GlcNS) is the most beneficial modification for binding and endocytosis via both Stabilin
receptors. In addition, our data suggest that a decasaccharide
is the minimal size for binding to the Stabilin receptors. These
findings define the physical parameters of the heparin structure
required for efficient clearance from blood circulation. These results will also aid in the design of synthetic heparins with desired clearance rates.
Keywords: Endocytosis, Endothelial Cell, Heparan Sulfate, Heparin, Receptors, Arixtra, Stabilin, Glycosaminoglycan, Liver
Abbreviations: UFH, unfractionated heparin; HARE, hyaluronic
acid receptor for endocytosis; HS, heparan sulfate; CS, chondroitin sulfate; Stab1, Stabilin-1; Stab2, Stabilin-2; LMWH, low
molecular weight heparin; IdoA, iduronic acid; PAPS, 3′-phosphoadenosine 5′-phosphosulfate; OST, sulfotransferase; ATIII,
antithrombin III; ESI, electrospray ionization; AnMan, 2,5-Anhydromannitol; GlcNTFA, N-trifluoroacetylated glucosamine; NST,
N-sulfotransferase.
Heparin is an anticoagulant drug that is widely prescribed
for procedures in which blood is handled, including surgery, blood/plasma donation, coronary and peripheral vascu-

lar procedures, thrombosis, dialysis, and in the washing and
preparation of medical equipment (1). The current supply of
heparin is derived from the pulp of porcine small intestine and
is harvested as unfractionated heparin (UFH)3 with polymeric
chain lengths ranging from 3,000 to 30,000 Da. UFH is depolymerized into smaller sizes with chain lengths ranging from
2000 to 8000 Da to yield the products known as low molecular
weight heparin (LMWH). Generally, both UFH and LMWH
are fast-acting coagulants with different clearance rates. UFH
has a circulatory half-life of 30–60 min, in contrast to LMWH,
which has a half-life of 2–6 h (2, 3).
The clearance of heparin is primarily mediated by liver sinusoidal endothelial cells (4). The primary receptor responsible for the systemic clearance of heparin is Stabilin-2/HARE
(Stab2)(HARE, hyaluronic acid receptor for endocytosis) (5, 6).
Thus, the binding affinity of heparin to Stab2 likely relates to
the clearance rate of heparin. Stab2 is presented on the cell surface as two isoforms: 315- and 190-kDa type I receptors. A subset of the 315-kDa receptor undergoes proteolytic cleavage to
produce the smaller 190-kDa receptor. Both 315-kDa and 190kDa Stab2 receptors bind to and participate in systemic clearance of heparin (7, 8). The binding affinity of Stab2 to UFH
is higher than LMWH, suggesting that interactions between
Stab2 and heparin are dependent on the length of the polymer.
Stab2 receptors are also responsible for clearing other glycosaminoglycans, including hyaluronic acid and chondroitin sulfates. It is known that the Stab2 binding domain(s) for heparin
are distinct from the Link domain for binding hyaluronic acid
and chondroitin sulfates (9).
Stabilin-1 (Stab1) is a Stab2 homologous protein expressed
in humans, which has not been reported to bind to heparin
previously. The topological organization of Stab1 is similar to
Stab2 in that they share 21 EGF/EGF-like domains, seven Fasciclin-1 domains, and one X-link domain with an overall 41%
amino acid identity and 56% similarity. Stab1, like Stab2, is expressed in the endothelium of liver, lymph node, and spleen,
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Figure 1. Chemical structures of different HS constructs. A, the general structure of all 10 different constructs. The top left structure shows the structures of those constructs without iduronic acid residues. The top right structure shows the structures of those constructs with iduronic acid residues.
Each individual polysaccharide construct is shown in the table underneath those two generic structures. B, the structure of a decasaccharide (10-mer,
15b) that displays full binding ability to the Stabilin receptors as described under “Results.” To maintain clarity, the structures of other oligosaccharide
constructs are not shown. The abbreviated structures are listed in Table 1.

but is also uniquely expressed in activated macrophages and
continuous endothelial vasculature (10, 11), suggesting that
this receptor is immune-responsive. Both Stab1 and Stab2 bind
an array of ligands. Stab1 binds to SPARC (secreted protein
acidic and rich in cysteine) (12) and lactogen (13); Stab2 binds
to collagen propeptides (6) in addition to glycosaminoglycans.
The common ligands for both receptors are acetylated LDL (5,
14), GDF-15 (15), phosphatidylserine (16–18), and advanced
glycation end products (19).
Heparan sulfate (HS) is a glycosaminoglycan consisting
of repeating disaccharide units of glucuronic acid (GlcA) or
iduronic acid (IdoA) and glucosamine, with each of the saccharide units capable of carrying sulfo groups. The positions
of the sulfo groups, the location of the IdoA residues, and the
size of the HS chain determine its biological functions. Heparin is a special form of HS, carrying higher levels of sulfation
and IdoA. HS is a highly heterogeneous complex mixture.
Its biosynthesis involves the preparation of a polysaccharide
backbone and a series of sulfations and epimerization modifications. The enzymes that carry out these modification reactions have been expressed and purified (20). Utilizing recombinant HS biosynthetic enzymes, we demonstrated the
synthesis of HS polysaccharides with specific sulfation patterns (21, 22) and HS oligosaccharides with defined structures (23, 24). The synthesized polysaccharides and oligosaccharides act as valuable reagents to probe the structural
selectivity of HS in a given biological or biochemical experiment (20, 24).
In this study, we used synthetic HS polysaccharides and
oligosaccharides to probe the structural requirements for binding to the Stabilin receptors. We report that 3-O-sulfation has
a significant impact on binding/endocytosis. The size of poly-

mer also plays a role in endocytosis. We describe the minimal size and sulfations required for endocytosis in recombinant cell lines and in murine liver endothelium. For the first
time, we demonstrate that Stab1 is also responsible for the internalization of heparin in cell culture and in binding assays
performed in vitro. Our findings advance the understanding of
the mechanism for clearing HS and heparin. Our results also
provide a molecular basis for designing heparin anticoagulant
drugs with different clearance rates.

Experimental Procedures
Materials, Solutions, and Buffers — Heparin (or unfractionated heparin) was from Sigma. Fondaparinux (Arixtra®)
was purchased from a local pharmacy. Flp-In 293 cells, serum,
high glucose Dulbecco’s modified Eagle’s medium (DMEM),
Hygromycin B, Zeocin, and glutamine were from Invitrogen.
Western blot analysis was completed by either colorimetric or
chemiluminescence detection of blotted protein. Anti-V5 antibodies and resins were from Bethyl Laboratories (Montgomery, TX). Other materials, reagents, and kits were obtained
as described recently (9). Tris-buffered saline with Tween 20
(TBST) contains 20 mm Tris-HCl, pH 7.0, 150 mm NaCl, and
0.1% Tween 20. TBST/BSA is TBST with 1.0% (w/v) bovine
serum albumin (BSA). Phosphate-buffered saline (PBS) contains 137 mm NaCl, 8 mm Na2HPO4, 1.5 mm KH2PO4, 2.7 mm
KCl, pH 7.2. Hanks’ buffered saline solution contains 5 mm
KCl, 0.4 mm KH2PO4, 0.8 mm MgSO4, 137 mm NaCl, 0.3 mm
Na2HPO4, 5.5 mm glucose, 1.26 mm CaCl2, 0.5 mm MgCl2, and
28 μm phenol red; at the time of use, 3.5 g/100 ml of NaHCO3
was added, and the pH was adjusted to 7.2 with HCl. Endocytosis Medium contains DMEM supplemented with 0.05% BSA.
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Preparation of 35S-labeled HS Constructs — A total of 27
HS constructs were prepared for this study using a chemoenzymatic approach published previously (Figure 1 and Table 1) (22, 24). Constructs 1 through 10 (Figure 1A) are polysaccharide constructs differing in sulfation types and IdoA
content, whereas constructs 11 through 23 are oligosaccharide constructs ranging from hepta- to nonadecasaccharides.
A representative structure of a decasaccharide (15b) is shown
in Figure 1B. For the synthesis of polysaccharide constructs (1
through 10), N-sulfo heparosan was used as a starting material and incubated with the appropriate enzymes and the sulfo
donor 3′-phosphoadenosine 5′-phosphosulfate (PAPS) (22).
The polysaccharide products were analyzed by disaccharide
analysis to confirm the anticipated sulfations (25). To prepare
the oligosaccharide constructs (11 through 23), both elongation and modification steps were involved. During the elongation step, a disaccharide starting material (GlcA-AnMan) was
first elongated to the desirable size with KfiA (N-acetyl glucosaminyl transferase of Escherichia coli K5 strain) and pmHS2
(Pasteurella multocida heparosan synthase 2) in the presence
of UDP-GlcA and UDP-GlcNAc or UDP-GlcNTFA. The elongated products were confirmed by electrospray ionization
mass spectrometry (ESI-MS). The oligosaccharides were then
converted to N-sulfo oligosaccharides by treating with triethylamine followed by N-sulfotransferase modification. The
products were demonstrated to have the anticipated molecular size and purity by ESI-MS. The ESI-MS spectra of the octato decasaccharides are shown in Supplemental Figure S1. For
those oligosaccharides larger than dodecasaccharides, the ESIMS spectra are shown in separate publications (23).*
The oligosaccharides were then modified by C5-epimerase,
2-O-sulfotransferase (2-OST), 6-O-sulfotransferase 1 and 3 (6OST-1 and 6-OST-3), and 3-O-sulfotransferase 1 (3-OST-1). After the modifications, a mixture of oligosaccharides with different levels of sulfation was obtained as determined by DEAE
(diethylaminoethyl)-HPLC (Supplemental Figure S2). To introduce a 35S label to the polysaccharides or oligosaccharides,
[35S]PAPS replaced unlabeled PAPS. 35S-labeled 3-O-sulfated
heparin was prepared by incubating heparin with 3-OST-5 enzyme and [35S]PAPS, and the product was purified by DEAE
chromatography.
The procedures for preparing the N-sulfo heparosan, PAPS
and [35S]PAPS, UDP-GlcNTFA, and disaccharide (GlcA-AnMan) starting materials are described elsewhere (22, 23, 27).
The enzymes used for the synthesis, including KfiA, pmHS2,
NST, C5-epimerase, 2-OST, 6-OST-1, 6-OST-3, and 3-OST-1,
were expressed in E. coli as described previously (24).
Expression Plasmids — The cDNA for human Stab1 (a
kind gift of J. Kzhyshkowska, University of Heidelberg) and
Stab2/315-HARE were ligated into the multi-cloning site of
the pcDNA5/FRT/V5-6×HIS-TOPO vector. The Stab2/190HARE cDNA encoding the C-terminal 1416 amino acids is
cloned in pSecTag/FRT/V5–6×HIS-TOPO, which provides a
secretion signal for the 190-HARE protein (8). Plasmids encoding the secreted ectodomain were generated by single primer
deletion mutagenesis (7) in which the transmembrane and cytoplasmic domain encoding regions were deleted, and the resulting plasmids were then used to create stable cells that secreted properly folded and functional ectodomains in the
medium. The ectodomains comprised amino acids M1-P2475
for Stab1, M1-T2458 for Stabilin-2/315-HARE, and S1136* Y. Xu, E. H. Pempe, and J. Liu, submitted for publication.

et al. in

The Journal

of

B i o l o g i c a l C h e m i s t ry , 287 (2012)

V2453 for Stab2/190-HARE.
Endocytosis Assays — Stably transfected cells expressing
Stab1 or Stab2 receptors or only Hygromycin B-resistant (empty
vector) were plated in 24-well dishes and grown in DMEM with
8% FBS and 50 μg/ml Hygromycin B for at least 2 days prior to
the experiments. The cells were incubated at 37 °C for 3 h with
fresh Endocytosis Medium supplemented with labeled [35S]HS
constructs (2.0 × 104 cpm/ml). For those experiments utilizing
antithrombin III (ATIII), the [35S]HS constructs were preincubated with ATIII (0.2 mg/ml) for 30 min prior to diluting 10fold in endocytosis medium. Specific binding or endocytosis
was assessed in the presence of excess unlabeled heparin (0.1
mg/ml) to determine background count per minute (cpm) values. These values were subtracted from all data points to determine the specific [35S]HS endocytosis. At the termination
times, cells were washed three times with ice-cold Hanks’ buffered saline solution and lysed in 0.3 n NaOH, and radioactivity
and protein content were determined and expressed as cpm/
μg of protein ± S.D. 35S radioactivity of all samples was measured by a Beckman-Coulter LS6500 scintillation counter. Nonspecific binding/background radiation levels were consistently
between 16 and 20 cpm for all experiments.
Direct Binding Assays — To assess direct protein-HS binding, ectodomains of each receptor were expressed and secreted
in stable cell lines. The ectodomains were immunoprecipitated
with a goat anti-V5 resin (Bethyl Laboratories), washed with
TBS, and then incubated with 4.0 × 105 cpm of each [35S]HS
construct for 1.5 h under rotation. The resin was centrifuged,
washed three times with TBS, and then placed in scintillation
fluid and quantified by a Beckman-Coulter LS6500 scintillation counter. The amount of protein on the resin was quantified by separation with 5% SDS-PAGE, blotted, and probed
with rabbit anti-V5 antibody (Bethyl Laboratories), and images were captured on film.
Assessment of Liver Clearance — All animal procedures
were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Nebraska under the Association for Assessment and Accreditation of Laboratory Animal
Care (AAALAC) guidelines. BALB/c mice were placed under
general anesthesia (isoflurane) on a warming platform during
the entire procedure. Once unconsciousness was confirmed, the
mice were injected via the lateral tail vein using a 27-gauge ×
1/2 inch needle with 0.053 μCi of 35S-labeled HS construct. The
radiolabeled material was allowed to circulate for 10 min followed by abdominal exposure and severance of the descending
aorta abdominalis for bleed out. The liver was collected, briefly
washed to get rid of residual blood, cut into smaller (~0.1 g)
pieces, weighed, and then homogenized with a PowerGen 125
(Fisher) tissue homogenizer in 0.75 ml of 1% Nonidet P-40. Homogenized tissue was then spun at 12,000 × g for 2 min to clear
out insoluble material, and supernatants were mixed with 4 ml
of scintillation fluid and counted.

Results
35S-labeled

Heparin Binds Stabilin-1 and Stabilin-2 Receptors — Cell lines stably expressing Stab2 and empty vector
were created as described previously (7, 8). The cell line stably expressing human Stab1 cDNA was also constructed with
identical methodology. The expressions of Stab1 and Stab2
are shown by a representative Western blot of the cell lysates
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Figure 2. Internalization of 3-O-sulfated heparin via Stab1 and Stab2.
A, cell lysates (20 μg) were separated by 5% SDS-PAGE, blotted to nitrocellulose, and probed with anti-V5 antibody. Lane 1, Stab2/190-HARE;
lane 2, Stab2/315-HARE; lane 3, Stab1. B, stable cell lines expressing
Stab1 (white bar), both Stab2 isoforms (gray bars), and empty vector (EV,
black bar) were incubated with 35S-labeled 3-O-sulfated heparin for 3 h.
The dotted line represents nonspecific binding values and is subtracted
from the data to determine receptor-specific endocytosis. Endocytosis
was evaluated by cpm/μg of cell lysate protein for each cell line, mean
± S.D., n = 3.

probed with the anti-V5 antibody (Figure 2A). The expression
of the recombinant receptors is similar to the native receptors
in that a percentage of the full-length Stab2 is processed to the
smaller 190-kDa isoform and Stab1 is expressed as a tight doublet at around 323 kDa. The level of expression for 315-HARE
Stab2 is less than that of 190-HARE Stab2 in the recombinant
cell lines; thus, the HS binding values for the 315-HARE cell
line are typically lower.
35S-labeled heparin was used as a positive control to assess
binding and endocytosis throughout the study. The 35S-labeled heparin (or 35S-labeled 3-O-sulfated heparin) was specifically labeled at the 3-OH position by incubating heparin
with 3-OST-5 enzyme and [35S]PAPS. As shown in Figure 2B,
we observed an elevated level of endocytosis for 35S-labeled
heparin in cells expressing Stab receptors when compared
with cells expressing the empty vector. Stab1, the weakest receptor for heparin, bound heparin at a level slightly above
that of the negative control (empty vector cells). Two Stab2
isoforms (190-HARE and 315-HARE) displayed significantly
higher levels of internalization of heparin than the negative
control (Figure 2B).
Structural Requirement for HS Endocytosis — HS contains
various types of sulfations and GlcA versus IdoA residues. To
understand the structural selectivity for binding to the Sta-
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bilin receptors, we chemoenzymatically produced a series of
HS polysaccharides with specific modifications ranging from
N-sulfation alone on the glucosamine residue (construct 1) to
the much more complex sulfation patterns commonly found
in heparin and HS (constructs 8 and 9) (Table 1 and Figure 1).
We observed that the polysaccharides carrying N-sulfation
only or a combination of N-sulfation and a single O-sulfation
type display low internalization via the Stabilin receptors (Figure 3, constructs 1-5). Increasing the O-sulfation types (or combining N-sulfation with 2-O- and 6-O-sulfation) elevated the
internalization via the Stabilin receptors (Figure 3, constructs
6 and 7). Interestingly, the addition of 3-O-sulfation showed
the highest internalization rate (Figure 3, constructs 8 and 9).
Given the fact that 3-O-sulfation represents a rare modification
in HS (28), our results suggest that Stabilin receptors recognize
unique sulfation patterns independent of the charge density.
This conclusion was further strengthened by the competitive
inhibition using antithrombin (see Figure 5) as well as by employing the oligosaccharide substrates as described below (see
Figure 7). Constructs 6 and 8 (with IdoA residues) and 7 and
9 (without IdoA residues) exhibited similar binding to the receptors, suggesting that the presence of IdoA has no significant effect on endocytosis.
We also examined the direct binding between the polysaccharide constructs and different Stabilin receptor ectodomains
(Figure 4). The Stabilin receptors were captured from the medium of cells secreting the corresponding receptor (Figure 4A)
using anti-V5 antibody coupled to Sepharose resin and exposed
to 35S-labeled HS constructs. As anticipated, a similar trend was
observed for direct binding, namely that higher sulfation levels for a given construct lead to greater binding to the Stabilin
receptors (Figure 4, B–D). In these experiments, the empty vector negative control was used as a baseline for nonspecific polysaccharide binding due to the inherent “stickiness” of the high
charge on the HS to the antibody resin. Again, the polysaccharides carrying 3-O-sulfation (constructs 8 and 9) exhibited the
highest binding toward the Stabilin receptors. We also observed
that the binding levels of 8 and 9 to the 190-HARE and Stab1
receptors were comparable, suggesting that the receptor makes
no distinction between IdoA and GlcA (Figure 4, B and D). Although slightly higher binding was observed for construct 9
with 315-HARE (Figure 4C), we cannot conclude that IdoA decreases the binding of HS to the receptor.
Antithrombin III Competes with Stabilins for HS Binding — ATIII is a serine protease inhibitor that regulates blood
coagulation by targeting thrombin and factor Xa (29). Inhibition of these targets occurs via the formation of a 1:1 complex between ATIII and HS that contains a specific heparin
pentasaccharide sequence for ATIII binding (30, 31). The 3-Osulfated glucosamine residue within the pentasaccharide is
the last modification step during heparin biosynthesis and is
carried out by 3-OST-1 (32). Because the 3-O-sulfated polysaccharides exhibited increased Stabilin-mediated endocytosis, we asked whether Stabilin and ATIII bind to the same
site in HS. First, we demonstrated the inhibition of [35S]heparin endocytosis with Stab1 cells in the presence of increasing
concentrations of ATIII (Figure 5A). We utilized both ATIIIbinding polysaccharide constructs, constructs 8 and 9 containing the 3-O-sulfation, and ATIII-nonbinding polysaccharide constructs, constructs 6 and 7. As expected, constructs
6-9 displayed distinct Stabilin-mediated internalization effects in the presence and absence of ATIII. ATIII did not interfere with the endocytosis of constructs 6 and 7 in all three

GlcA-GlcNS6S- (IdoA ± 2S-GlcNS6S)3-GlcA-AnMan

GlcA-GlcNS6S ± 3S- (IdoA ± 2S-GlcNS6S)3-GlcA-AnMan

GlcA-GlcNS6S ± 3S- (GlcA ± 2S-GlcNS6S)4-GlcA-AnMan

GlcA-GlcNS6S- (IdoA ± 2S-GlcNS6S)4-GlcA-AnMan

GlcA-GlcNS6S ± 3S- (IdoA ± 2S-GlcNS6S)4-GlcA-AnMan

GlcNS6S- (GlcA ± 2S-GlcNS6S ± 3S)3- (GlcA-GlcNAc6S)2GlcA-GlcNS6S-GlcA-AnMan

GlcNS6S- (IdoA ± 2S-GlcNS6S ± 3S)3- (GlcA-GlcNAc6S)2GlcA-GlcNS6S-GlcA-AnMan

GlcNAc6S- (GlcA ± 2S-GlcNS6S ± 3S)4- (GlcA-GlcNAc6S)2GlcA-GlcNS6S-GlcA-AnMan

GlcNAc6S- (IdoA2S-GlcNS6S ± 3S)4- (GlcA-GlcNAc6S)2GlcA-GlcNS6S-GlcA-AnMan

GlcNS6S- (IdoA2S-GlcNS6S ± 3S)5- (GlcA-GlcNAc6S)2GlcA-GlcNS6S-GlcA-AnMan

GlcNS6S- (IdoA2S-GlcNS6S ± 3S)5- (GlcA-GlcNAc6S)2GlcA-GlcNS6S-GlcA-AnMan

15b

16

17a

17b

18

19

20

21

22

23

GlcNAc6S-GlcA-GlcNS6S3S-IdoA2S-GlcNS6S-GlcA-AnMan

11

15a

Heparin, (-IdoA2S-GlcNS6S-)n and (-GlcA-GlcNS ± 6S ± 3S-)m

10

GlcA-GlcNS6S ± 3S- (GlcA ± 2S-GlcNS6S)3-GlcA-AnMan

(-GlcA2S-GlcNS6S-)n and (-GlcA-GlcNS ± 6S ± 3S-)m

9

14

(-GlcA-GlcNS ± 6S ± 3S-)n and (-IdoA2S-GlcNS6S-)m

8

GlcNS6S-GlcA-GlcNS6S ± 3S- (IdoA ± 2S-GlcNS6S)2-GlcA-AnMan

(-GlcA2S-GlcNS6S-)n

7

13b

(-IdoA2S-GlcNS6S-)n

6

GlcNS6S-GlcA-GlcNS6S- (IdoA ± 2S-GlcNS6S)2-GlcA-AnMan

(-IdoA2S-GlcNS-)n

5

13a

(-GlcA2S-GlcNS-)n

4

GlcA-GlcNS6S- (IdoA ± 2S-GlcNS6S)2-GlcA-AnMan

(-IdoA-GlcNS6S-)n

3

GlcA-GlcNS6S ± 3S- (IdoA ± 2S-GlcNS6S)2-GlcA-AnMan

(-GlcA-GlcNS6S-)n

2

12b

(-GlcA-GlcNS-)n

1

12a

Anticipated disaccharide repeating unit

Constructs

Nonadecasaccharide (19-mer)

Nonadecasaccharide (19-mer no IdoA)

Heptadecasaccharide (17-mer)

Heptadecasaccharide (17-mer no IdoA)

Synthesis started from pure N-sulfo, N-acetylated nonadecasaccharide

Synthesis started from pure N-sulfo, N-acetylated nonadecasaccharide

Synthesis started from pure N-sulfo, N-acetylated heptadecasaccharide

Synthesis started from pure N-sulfo, N-acetylated heptadecasaccharide

6-O-[35S]sulfation

6-O-[35S]sulfation

6-O-[35S]sulfation

6-O-[35S]sulfation

6-O-[35S]sulfation

6-O-[35S]sulfation

6-O-[35S]sulfation

6-O-[35S]sulfation

6-O-[35S]sulfation

of

Synthesis started from pure N-sulfo, N-acetylated pentadecasaccharide

Synthesis started from pure N-sulfo, N-acetylated pentadecasaccharide

Synthesis started from pure N-sulfo decasaccharide

Synthesis started from pure N-sulfo decasaccharide

Synthesis started from pure N-sulfo dodecasaccharide

6-O-[35S]sulfation

6-O-[35S]sulfation

6-O-[35S]sulfation

N-[35S]sulfation

N-[35S]sulfation

N-[35S]sulfation

N-[35S]sulfation

3-O-[35S]sulfation

3-O-[35S]sulfation

N-[35S]sulfation

N-[35S]sulfation

N-[35S]sulfation

N-[35S]sulfation

N-[35S]sulfation

N-[35S]sulfation

N-[35S]sulfation

N-[35S]sulfation

The Journal

Pentadecasaccharide (15-mer)

Pentadecasaccharide (15-mer no IdoA)

Dodecasaccharide (12-mer with 3-O-sulfation)

Dodecasaccharide (12-mer no 3-O-sulfation)

Synthesis started from pure N-sulfo decasaccharide

Synthesis started from pure N-sulfo decasaccharide

labeling site

N-[35S]sulfation

35S

et al. in

Dodecasaccharide (12-mer no IdoA)

Decasaccharide (10-mer with 3-O-sulfation)

Decasaccharide (10-mer no 3-O-sulfation)

Synthesis started from pure N-sulfo decasaccharide

Synthesis started from pure N-sulfo nonasaccharide

Synthesis started from pure N-sulfo nonasaccharide

Synthesis started from pure N-sulfo octasaccharide

Synthesis started from pure N-sulfo octasaccharide

Synthesis started from pure N-sulfo, N-acetylated heptasaccharide

3-OST-5

NST, 2-OST, 6-OST, and 3-OST-1

NST, C5-epi, 2-OST, 6-OST, and 3-OST-1

NST, 2-OST, and 6-OST

NST, C5-epi, 2-OST, and 6-OST

NST, C5-epi, and 2-OST

NST and 2-OST

NST, C5-epi, and 6-OST

NST and 6-OST

NST

Modification steps involved

Pempe

Decasaccharide (10-mer no IdoA)

Nonasaccharide (9-mer with 3-O-sulfation)

Nonasaccharide (9-mer no 3-O-sulfation)

Octasaccharide (8-mer with 3-O-sulfation)

Octasaccharide (8-mer no 3-O-sulfation)

Heptasaccharide (7-mer)

Polysaccharide, >6,000 Da

Polysaccharide, >6,000 Da

Polysaccharide, >6,000 Da

Polysaccharide, >6,000 Da

Polysaccharide, >6,000 Da

Polysaccharide, >6,000 Da

Polysaccharide, >6,000 Da

Polysaccharide, >6,000 Da

Polysaccharide, >6,000 Da

Polysaccharide, >6,000 Da

Size of the construct

Table 1. Summary of the polysaccharide and oligosaccharide constructs
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cell lines (Figure 5, B and C). In contrast, endocytosis of constructs 8 and 9 was significantly decreased, but not entirely
inhibited, in all three cell lines (Figure 5, D and E). It is also
interesting to note that there is a significant amount of internalization of 35S-polysaccharide after ATIII inhibition (constructs 8 and 9). The internalization levels that could not be
inhibited by ATIII for constructs 8 and 9 were similar to the

Figure 3. Modifications of heparosan determine internalization rates.
The empty vector (EV, black bars), Stab1 (white bars), and Stab2/190HARE (gray bars) cell lines were incubated with equal amounts of each
modified HS construct for 3 h. The cells were then washed, and the lysates were counted by scintillation autoradiography. The amounts of
[35S]HS constructs were determined by specific cpm/μg of protein cell
lysate, mean ± S.D., n = 3.
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ones observed for constructs 6 and 7. These data suggest that
ATIII and membrane-bound Stabilin receptors bind to the
same site in HS for internalization. Our data also suggest that
Stabs bind to HS in two modes. One mode is that it binds
to the site that also interacts with ATIII, which may be the
more significant interaction site; another mode is that it binds
to highly negatively charged polysaccharides without structural selectivity.
The Size of the Saccharide Versus Endocytosis in Stab1 and
Stab2 Cell Lines — We next investigated the length of heparin required for endocytosis. First, we used heparin oligosaccharides of different lengths ranging from a 10-mer to a 19-mer
(constructs 14-23). None of these oligosaccharides were taken
up by the empty vector cells including those without IdoA residues (data not shown). Next, we tested all of the constructs 1423 with both Stab1 and Stab2 (315-HARE) cell lines. As summarized in Figure 6B, both the 7-mer (11) and 8-mer (12) exhibit
very little endocytosis, but endocytosis is slightly increased in
the 9-mer (13b), especially for the Stab1 cells. The biggest jump
in the incidence of endocytosis occurs when one additional
sugar is added to make a 10-mer (15b). The amount of internalized oligosaccharides remained steady up to a nonadecasaccharide (19-mer, 23). From these data, the minimal size for significant endocytosis is a 10-mer for both Stab1 and Stab2 receptors.
Similar results were observed for the 190-HARE receptor.
We next compared the internalization of the 7-mer (11) and
19-mer (23) for internalization in full-length Stab1 and Stab2
cell lines. We did not observe any internalization of the 7-mer
in cells expressing either Stab1 (white bars) or Stab2/315-HARE
(gray bars) (Figure 6B). Furthermore, we did not observe a sig-

Figure 4. Direct binding of HS oligosaccharides with Stab1 and Stab2 ectodomains. Ectodomains/secreted versions of each receptor were immunopurified by V5 resin and were either subject to 5% SDS-PAGE, blotted, and probed with anti-V5 antibody (Lane 1, s190-HARE/Stab2; lane 2, s315-HARE/
Stab2; lane 3, sStab1) (A) or incubated with an equal amount of each HS construct for 1.5 h under rotation (B–D). The resin was washed with Tris-buffered saline three times and then mixed with scintillation mixture, and cpm was determined. Counts per minute were normalized to the amount of protein on the resin.
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Figure 5. ATIII significantly inhibits Stabilin-mediated heparin endocytosis. A, a dose-response curve for ATIII against heparin was generated by incubating Stab1 cells with labeled heparin and varying amounts of ATIII. At each concentration, cells were processed as described under “Experimental
Procedures.” The dotted line represents the threshold for nonspecific binding. B–E, an equal amount of each construct (6-9) was preincubated with endocytosis medium (gray bars) or endocytosis medium supplemented with 0.2 mg/ml ATIII (white bars) and then added to each indicated cell line. After 3 h, cells were washed, and radioactivity and protein contents were determined as specific cpm/μg of protein, mean ± S.D., n = 4. For constructs 8
and 9 (D and E), the statistical differences in internalization in the presence or absence of ATIII were p ≤ 0.05 for all cell lines in contrast to constructs
6 and 7 (B and C), which showed no significant difference. 3-O sulf., 3-O-sulfation.

nificant decrease in the internalization of the 19-mer (23) by
competition with the synthetic pentasaccharide, Arixtra, at 50fold molar excess. These results demonstrate that the minimal
length of a heparin oligosaccharide cleared by these cell lines
is at least 10 sugars in length and that the synthetic pentasaccharide is not cleared by cells expressing the Stabilin receptors.
3-O-Sulfation Is Required for Decasaccharides to Bind to
Stab Receptors and for Endocytosis — To further establish the
role of 3-O-sulfation and the size requirement for the binding
to Stab receptors, we utilized a series of oligosaccharides with
and without 3-O-sulfation. These experiments also utilized labeled heparin as a positive control (black bars) and a structurally defined heptasaccharide (7-mer, 11) (24) as a negative control. Both the Stab1 (Figure 7A) and the Stab2 (Figure 7B) cells
show robust endocytosis with heparin and no endocytosis

with 11. The oligosaccharides composed of eight or nine sugars without 3-O-sulfation (12a and 13a) did not show endocytosis in contrast to their 3-O-sulfated counterparts that exhibited marginal to very low endocytosis (12b and 13b, Figure
7, gray bars). This is in contrast with the 3-O-sulfated decasaccharide (15b) and dodecasaccharide (17b), which exhibit robust endocytosis with the dodecasaccharide that is almost
comparable with the heparin control (Figure 7, A and B). Furthermore, the deca- and dodecasaccharide without 3-O-sulfation (15a and 17a, white bars) were not internalized near the extent as their sulfated counterparts (gray bars). Taken together,
our data are consistent with the conclusions that 3-O-sulfation
plays a significant role in binding to Stab receptors in the endocytosis of heparin and that the minimum size for binding to
the Stab receptors is a decasaccharide.
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Figure 6. Size of oligosaccharide affects endocytic rates. A, Both Stab1
and Stab2/315-HAREcell lines were incubated with the 7-mer (11), 8-mer
(12b), 9-mer (13b), 10-mer (15b), 15-mer (19), and 19-mer (23) for 3
h. All cell lines were washed with Hanks’ buffered saline solution followed by determination of cpm by scintillation counting and protein by
the Bradford assay; mean ± S.D., n = 5. B, both radiolabeled 7-mer and
19-mer oligosaccharides were incubated for 3 h with Stab1 cells (white
bars) and Stab2/315-HARE cells (gray bars). To confirm that the short synthetic pentasaccharide does not bind with any of the Stabilin receptors,
we added a 50-fold excess clinical grade Arixtra (Ax) to the endocytosis medium to both the 19-mer (black bars) and the 7-mer (not shown).
After a 3-h incubation for all samples, the cells were washed and lysed,
and radioactivity and protein were determined, mean ± S.D., n = 3. The
Stab2/190-HARE cell lines showed similar results (data not shown).

3-O-Sulfated Decasaccharide Retention in Liver Is Similar
to Heparin — It is known that UFH is retained by liver to display a fast clearance rate, whereas Fondaparinux (a pentasaccharide) is not and displays a slow clearance rate in vivo (33).
Therefore, these size and sulfation parameters should hold
true if the Stabilin receptors are responsible for the bulk clearance of systemic heparin. To test this, we individually injected
mice via the tail vein with four 35S-labeled constructs: heparin (positive control); 7-mer (21, negative control); the decasaccharide without 3-O-sulfation (12a); and the decasaccharide
with 3-O-sulfation (12b) (Figure 8). Mice under general anesthesia were injected with equal amounts of radioactive material that was allowed to circulate; the mice were then bled out,
and the livers were collected and processed for scintillation
counting. We found that the 7-mer (21, white bar) was not retained in the liver. The decasaccharide with 3-O-sulfation (12b,
dark gray bar) was retained in the liver to a similar degree as
heparin (black bar). In contrast, the retention of the decasaccharide without 3-O-sulfation (12a) in the liver was significantly
reduced. To this end, our data suggest that the 3-O-sulfation
contributed to the retention in liver in vivo.
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Figure 7. The 3-O-sulfated decasaccharide is the minimal size and
modification required for binding to the Stabilin receptors. Both Stab1
(A) and Stab2/315-HARE (B) were incubated with heparin (positive control, black bar) and ultralow molecular weight heparin (7-mer, negative control), 3-O-sulfated oligosaccharides (12b, 13b, 15b, 17b; dark
gray bars), and non-3-O-sulfated oligosaccharides (12a, 13a, 15a, 17a;
white bars) for 3 h. Endocytosis of each oligonucleotide was confirmed
by washing the cells with Hanks’ buffered saline solution and determining radioactivity and protein levels, mean ± S.D., n = 3.

Discussion

Understanding the clearance rate of heparin has significant clinical implications for improving the safety of heparin-based drugs. For surgical applications, a fast-clearing heparin drug is preferred, allowing the anticoagulant
effect to rapidly disappear after the operation and thus reducing the risk for bleeding side effects. In contrast, a slowclearing heparin is more desirable for patients with ongoing
use, avoiding repetitive dosing. Indeed, UFH is widely used
in surgical procedures and kidney dialysis, whereas LMWH
and Fondaparinux are more commonly used as prophylactic
agents among high risk patients prone to thrombosis (34, 35).
Although it is known that the size of the heparin chain plays
a role in the rate of clearance in patients, the precise structural requirements for regulating clearance remain uncharacterized. Previous studies have demonstrated that a liver
endothelial cell receptor, known as Stab, is primarily responsible for heparin clearance (5). By taking advantage of our
recent success in synthesizing heparins (22, 24), we investigated the contribution of the sulfation and the size of heparin to the binding to Stab proteins. Our results provide a
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Figure 8. 3-O-sulfation is required for efficient liver retention. Mice
were injected via the tail vein with equal amounts of labeled heparin
(black bar), 7-mer (11, white bar), decasaccharide without 3-O-sulfation
(15a, light gray bar), or decasaccharide with 3-O-sulfation (15b, dark
gray bar). After a short incubation time, mice were bled out, and livers were processed for scintillation counting. The data were measured
by (cpm/mass of liver) of at least three liver samples from each mouse
divided by the total cpm injected. Three mice were used for each construct (n = 3 ± S.E.).

molecular basis for designing synthetic heparins with desired clearance rates for unique clinical applications.
Our study reveals two binding modes between heparin and
Stab proteins. In one binding mode, the heparin polysaccharide binds to Stab1/2 nonspecifically; such binding requires a
long polysaccharide chain. Another binding mode is specific,
in which Stab proteins recognize a saccharide domain containing a 3-O-sulfo group. In the specific binding mode, a much
shorter oligosaccharide is sufficient to display high affinity to
Stabs. We also demonstrate that a 3-O-sulfated decasaccharide
displays higher retention in the liver in mice when compared
with its counterpart without 3-O-sulfation, suggesting that
Stab binding affinity correlates to the clearance in vivo.
Our data also suggest that Stab proteins recognize a unique
saccharide sequence. Although we do not know the precise
saccharide structure recognized by the Stabilin receptors at
the present time, some overlaps between the Stab-binding sequence and ATIII-binding sequence exist. We know that 3-Osulfation is a critical modification for displaying high binding
affinity to ATIII and for carrying anticoagulant activity (36).
Further, competitive binding of the Stab receptors and ATIII
to heparins was observed in this study. The mechanistic effect
of 3-O-sulfation on the binding to the Stabilin receptors is currently unknown. We postulate that this effect is unlikely to be
purely attributed to an increase in charge density because 3-Osulfation is a rare modification in HS (29). A recent study suggests that 3-O-sulfation may affect the conformation of neighboring IdoA2S residues to rearrange the positioning of sulfo
groups (37). In addition, previous studies have shown that
one natural highly sulfated chondroitin sulfate (CS-D) did not
compete with heparin in contrast to other similar chondroitin
sulfates (CS-B, CS-E) that demonstrated some degree of competition, providing evidence that charge is not the only determinant for heparin binding to the Stabilins (9).
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This is the first study demonstrating the structural selectivity of heparin binding to Stab1. The Stab1 receptor is expressed in the liver sinusoidal endothelium as well as in alternatively activated macrophages (11) and other physiological
niches (38) and may play a role in both systemic and localized
clearance of heparinoid molecules. Activated macrophages
may modulate the amount of dermatan sulfate in wound fluids that promote FGF-2 activity (39, 40). It is possible that Stab
1 plays a role in regulating the amount of anticoagulant HS in
wound fluid.
It should be noted that the rate of endocytosis also depends
on the concentration of Stab receptors on the cell surface. The
190-HARE Stab2 isoform always showed the highest increase
in endocytosis because these cells produce more receptor per
microgram of cell lysate than the other two cell lines. Not surprisingly, the liver endothelial cells exhibit a much higher ratio of 190/315-HARE Stab2 than the recombinant cell lines,
which may account for the rapid uptake of heparin within the
liver (41). The consistently lower internalization rate of heparin in the Stab1 cells may be reflective of the amount of total surface receptor available to bind and internalize heparin,
a lower binding affinity, or the unavailability to bind ligand
due to the very short transient time on the cell surface. Others
have reported the very short transient time of Stab1 on the cell
surface (11, 42). In these experiments, we noticed a discrepancy in binding versus endocytosis. Our in vitro binding assays
by immunoprecipitation of the ectodomain of Stab1 revealed
that the binding of the HS oligomers was qualitatively about
as high as that of the Stab2 ectodomains. This contrasts with
the cell-based assays and reveals that a combination of surface
availability and rapid turnover, not binding affinity, may be
responsible for lower endocytic rates in Stab1 cells. In addition, the expression of Stab receptors can be regulated by other
cellular mechanisms. A genetic screen in which human umbilical vein endothelial cells activated with VEGF revealed an increase of Stab1 expression reveals that growth factors and cytokines are able to alter endocytosis profiles of tissues (26).
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Suppl. Fig. S1. ESI-MS analysis of pure N-sulfated oligosaccharides. A,
octasaccharide, measured MW: 1592.5 ± 0.5. B, nonasaccharide, measured MW:
1833.9 ± 0.8. C, decasaccharide, measured MW: 2009.9 ± 0.7. D, dodecasaccharide,
measured MW: 2427.4 ± 0.5.

Suppl. Fig. S2. DEAE-HPLC chromatograms of HS oligosaccharides. A,
Octasaccharide (12a); B, Nonasaccharide (13a); C, Decasaccharide without 3-Osulfation (15a); D, Decasaccharide with 3-O-sulfation (15b); E, Dodecasaccharide
without 3-O-sulfation (17a); F, Dodecasaccharide with 3-O-sulfation (17b). Multiple or
broad peaks indicates a mixture.
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